A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Cook Pharmica, a subsidiary of Bloomington-based medical device maker Cook Group, currently employs 575 workers who manufacture and package drugs for use in clinical trials or for sale on the market.
Indianapolis-based Eli Lilly and Co. and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for alleged infringement of patents that cover the testosterone treatment Axiron.
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Target Corp. has agreed to sell its pharmacy and clinic businesses to the drugstore chain CVS Health Corp. for about $1.9 billion in a deal that combines the resources of two retailers seeking to polish their health care reputations.
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
